Trial Profile
A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2019
Price :
$35
*
At a glance
- Drugs Volociximab (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors IVERIC bio
- 01 Oct 2014 New trial record